Vaxcyte, Inc. (NASDAQ:PCVX) Stock Position Reduced by Point72 Asset Management L.P.

Point72 Asset Management L.P. decreased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 30.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 251,055 shares of the company's stock after selling 108,741 shares during the quarter. Point72 Asset Management L.P. owned approximately 0.20% of Vaxcyte worth $20,551,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Whipplewood Advisors LLC acquired a new position in shares of Vaxcyte in the 4th quarter valued at approximately $28,000. Smartleaf Asset Management LLC increased its stake in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares during the last quarter. National Bank of Canada FI acquired a new stake in Vaxcyte in the fourth quarter valued at $41,000. Blue Trust Inc. raised its holdings in Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after acquiring an additional 371 shares in the last quarter. Finally, Assetmark Inc. boosted its stake in Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after acquiring an additional 775 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PCVX. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Bank of America lowered their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Needham & Company LLC restated a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on Vaxcyte in a research report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Finally, Guggenheim reiterated a "buy" rating and issued a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $136.50.

Vaxcyte Stock Down 2.9%

Shares of NASDAQ:PCVX traded down $0.97 during trading on Friday, hitting $32.98. 212,466 shares of the company traded hands, compared to its average volume of 1,922,627. The business's fifty day moving average is $39.37 and its 200-day moving average is $69.95. The stock has a market capitalization of $4.25 billion, a price-to-earnings ratio of -7.17 and a beta of 1.27. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period in the previous year, the company posted ($0.85) earnings per share. On average, analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Insider Activity

In related news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the sale, the chief operating officer now directly owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 3.10% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.